Adaptin Bio APTN
OTC APTN
$6.27 +0.00 (+0.00%)
At close: Aug 19, 2026 · 4:00 PM EDT

Adaptin Bio (APTN) Return on Equity [ROE] (2025)

Updated

Adaptin Bio (APTN) posted Return on Equity [ROE] of -368.37% for Q2 2025.

Analysis

Adaptin Bio (APTN) Return on Equity [ROE] (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 25.32%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 7.21%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 84.40%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 21.39%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 83.75%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -18.38%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 4.97%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 22.24%
10 Adaptin Bio 56.76 Mn 54.75 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -368.37%
API Access

Adaptin Bio Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=APTN&period=max&api_key=YOUR_API_KEY